The capricious character of nature

The on-going whole genome sequencing and whole cell assays of metabolites and proteins imply that complex systems could ultimately be mastered by perfecting knowledge into great detail. However, courses of nature are inherently intractable because flows of energy and their driving forces depend on each other. Thus no data will suffice to predict precisely the outcomes of e.g., engineering experiments. All path-dependent processes, most notably evolution in its entirety, display this capricious character of nature.Peer reviewe

Mycosis fungoides and Sezary syndrome : a population-wide study on prevalence and health care use in Finland in 1998-2016

Background Information about health care use and costs of cutaneous T-cell lymphoma (CTCL) patients is limited, particularly in a European setting. Methods In this population-wide study we set out to investigate prevalence, and trends in health care use in two CTCL subtypes, mycosis fungoides (MF) and Sezary syndrome (SS) over a time period of 19 years in 1998-2016 by using a nation-wide patient register containing data on all diagnosed MF and SS cases in Finland. Results The prevalence of diagnosed MF and SS rose from 2.04 to 5.38/100000, and from 0.16 to 0.36/100000 for MF and SS respectively during 1998-2016. We found a substantial decrease in inpatient treatment of MF/SS in the past two decades with a mean of 2 inpatient days/patient/year due to MF/SS in 2016, while the mean numbers of MF/SS related outpatient visits remained stable at 8 visits/year/patient. Most MF/SS-related outpatient visits occurred in the medical specialty of dermatology. In a ten-year follow-up after MF/SS diagnosis, the main causes for outpatient visits and inpatient stays were MF/SS itself, other cancers, and other skin conditions. Also cardiovascular disease and infections contributed to the number of inpatient days. Mean total hospital costs decreased from 11,600 eur/patient/year to 3600 eur/patient/year by year 4 of the follow-up, and remained at that level for the remainder of the 10-year follow-up. MF/SS accounted for approximately half of the hospital costs of these patients throughout the follow-up. Conclusions The nearly 3-fold increase in prevalence of diagnosed MF/SS during 1998-2016 puts pressure on the health care system, as this is a high-cost patient group with a heavy burden of comorbidities. The challenge can be in part answered by shifting the treatment of MF/SS to a more outpatient-based practice, and by adapting new pharmacotherapy, as has been done in Finland.Peer reviewe

Mycosis fungoides and Sezary syndrome : a population-wide study on prevalence and health care use in Finland in 1998-2016

Background Information about health care use and costs of cutaneous T-cell lymphoma (CTCL) patients is limited, particularly in a European setting. Methods In this population-wide study we set out to investigate prevalence, and trends in health care use in two CTCL subtypes, mycosis fungoides (MF) and Sezary syndrome (SS) over a time period of 19 years in 1998-2016 by using a nation-wide patient register containing data on all diagnosed MF and SS cases in Finland. Results The prevalence of diagnosed MF and SS rose from 2.04 to 5.38/100000, and from 0.16 to 0.36/100000 for MF and SS respectively during 1998-2016. We found a substantial decrease in inpatient treatment of MF/SS in the past two decades with a mean of 2 inpatient days/patient/year due to MF/SS in 2016, while the mean numbers of MF/SS related outpatient visits remained stable at 8 visits/year/patient. Most MF/SS-related outpatient visits occurred in the medical specialty of dermatology. In a ten-year follow-up after MF/SS diagnosis, the main causes for outpatient visits and inpatient stays were MF/SS itself, other cancers, and other skin conditions. Also cardiovascular disease and infections contributed to the number of inpatient days. Mean total hospital costs decreased from 11,600 eur/patient/year to 3600 eur/patient/year by year 4 of the follow-up, and remained at that level for the remainder of the 10-year follow-up. MF/SS accounted for approximately half of the hospital costs of these patients throughout the follow-up. Conclusions The nearly 3-fold increase in prevalence of diagnosed MF/SS during 1998-2016 puts pressure on the health care system, as this is a high-cost patient group with a heavy burden of comorbidities. The challenge can be in part answered by shifting the treatment of MF/SS to a more outpatient-based practice, and by adapting new pharmacotherapy, as has been done in Finland.Peer reviewe

Opioid trends in Finland : a register-based nationwide follow-up study

The opioid epidemic in the U.S has gotten payers, prescribers, and policymakers alike interested in trends in opioid use. Despite no recognized opioid crisis in Europe, several countries have reported an increase in opioid-related deaths, which has further prompted discussion on the need of monitoring of opioid prescriptions. This study was conducted to offer information on opioid use during the escalation of the U.S. opioid epidemic in Finland, a Nordic country with universal tax-based health care. This is a nationwide retrospective register-based cohort study on all individuals in Finland who were dispensed opioids in 2009-2017 (n of unique patients = 1,761,584). By using the unique personal identification code assigned to every Finnish resident, we linked data from nationwide registers on dispensed drugs, medical history, and socio-demographic parameters. We report a wide set of patient demographics, dispensing trends for all opioid Anatomical Therapeutic Chemical (ATC) classes, and reasons for opioid initiation based on diagnostic coding for the most recent health care visit. For a cohort of incident opioid users with a four-year wash-out period (n = 1 370 057), we also present opioid use patterns in a three-year follow-up: the likelihood of becoming a persistent user or escalating from weak to strong opioids. A steady 7% of the Finnish population were dispensed opioids annually in 2009-2017. The mean annual quantity of dispensed opioids per opioid patient increased between 2009 and 2017 by 33%, reaching 2 583 oral morphine equivalent mg (OMEQ)/patient/year in 2017. The median quantity of dispensed opioids was lower: 315 OMEQ/year/patient. Depending on the opioid ATC class, there were either increasing or decreasing numbers of patients who had been dispensed said opioid class, and also in the mean quantity. The most common reason for opioid initiation was post-surgical pain (20%), followed by musculoskeletal pain (15%), injury (8.3%), and non-postsurgical dental pain (6.2%). 94% of new opioid initiators started with a weak opioid, i.e. codeine or tramadol. 85% of the patients who had been dispensed a weak opioid were not dispensed an opioid subsequently 3-6 months after the first one, and 95% of them had not escalated to a strong opioid in a 3-year follow-up. The number of patients dispensed opioids in Finland did not change during the escalation of the opioid epidemic in the U.S., but there were changes in the quantity of opioids dispensed per patient. Opioid therapy was typically initiated with weak opioid, the initial dispensed prescription was relatively small, and escalation to strong opioids was rare. A considerable share of patients had been prescribed opioids for chronic non-cancer pain - a type of pain where the risk-benefit ratio of opioids is controversial.Peer reviewe

Multimorbidity and overall comorbidity of sleep apnoea : a Finnish nationwide study

The prevalence of sleep apnoea is increasing globally; however, population-based studies have reported a wide variation of prevalence estimates, and data on incidence of clinically diagnosed sleep apnoea are scant. Data on the overall burden of comorbidities or multimorbidity in individuals with incident sleep apnoea are scarce, and the pathways to multimorbidity have only marginally been studied. To study the current epidemiology of sleep apnoea in Finland, overall burden of comorbidities, and multimorbidity profiles in individuals with incident sleep apnoea, we conducted a register-based, nationwide, retrospective study of data from January 2016 to December 2019. The prevalence of clinically diagnosed sleep apnoea was 3.7% in the Finnish adult population; 1-year incidence was 0.6%. Multimorbidity was present in 63% of individuals at the time of sleep apnoea diagnosis. Of those with incident sleep apnoea, 34% were heavily multimorbid (presenting with four or more comorbidities). The three most common chronic morbidities before sleep apnoea diagnosis were musculoskeletal disease, hypertension and cardiovascular disease. In multimorbid sleep apnoea patients, hypertension and metabolic diseases including obesity and diabetes, cardiovascular diseases, musculoskeletal diseases and dorsopathies, in different combinations, encompassed the most frequent disease pairs preceding a sleep apnoea diagnosis. Our study adds to the few population-based studies by introducing overall and detailed figures on the burden of comorbidities in sleep apnoea in a nationwide sample and provides up-to-date information on the occurrence of sleep apnoea as well as novel insights into multimorbidity in individuals with incident sleep apnoea.Peer reviewe

Physicians discuss the risks of smoking with their patients, but seldom offer practical cessation support

Abstract Background Our aim was to study the smoking cessation-related 1) attitudes & experiences and 2) consultation practices of Finnish physicians and to determine if there is a relationship between the two. Methods An online survey on smoking cessation was sent to 39 % of all Finnish physicians, with emphasis on physicians working in fields relevant to smoking cessation. A total of 1141 physicians (response rate 15 %) responded to the online survey, 53 % of whom were employed in primary health care. A total of 1066 respondents were eligible for the analysis. The questionnaire included questions on the physician’s own smoking status, their attitudes and experiences on smoking cessation, and the implementation of smoking cessation in clinical practice. Two sub-scales concerning smoking-related consultation activities were constructed: one for conversation, and another for practical actions. Results The most common consultation activities (respondents who reported doing the following actions “nearly always”) were asking how much the patient smokes (65 %), marking smoking status in patient records (58 %) and recommending quitting to the patient (55 %). The least common activity was prescribing withdrawal medication (4 %). Primary care physicians were more active than those working in secondary health care in nearly all activities mapped. A positive attitude and experiences on smoking cessation were associated with actively offering withdrawal support. Those who were familiar with the local treatment guidelines for tobacco addiction were 30 % more active in offering practical cessation help to their patient. The respondents were more active in discussing smoking with their patients than in offering practical cessation help. Conclusion Physicians offer their patients practical cessation support relatively infrequently. Practical cessation calls for continuous education of physicians about the nature of tobacco and nicotine addiction, the role of smoking as a risk factor for various diseases, and the practical measures needed for smoking cessation. Secondary care physicians should acknowledge the authority they pose toward smoking patients

Multimorbidity and overall comorbidity of sleep apnoea: a Finnish nationwide study

The prevalence of sleep apnoea is increasing globally; however, population-based studies have reported a wide variation of prevalence estimates, and data on incidence of clinically diagnosed sleep apnoea are scant. Data on the overall burden of comorbidities or multimorbidity in individuals with incident sleep apnoea are scarce, and the pathways to multimorbidity have only marginally been studied. To study the current epidemiology of sleep apnoea in Finland, overall burden of comorbidities, and multimorbidity profiles in individuals with incident sleep apnoea, we conducted a register-based, nationwide, retrospective study of data from January 2016 to December 2019. The prevalence of clinically diagnosed sleep apnoea was 3.7% in the Finnish adult population; 1-year incidence was 0.6%. Multimorbidity was present in 63% of individuals at the time of sleep apnoea diagnosis. Of those with incident sleep apnoea, 34% were heavily multimorbid (presenting with four or more comorbidities). The three most common chronic morbidities before sleep apnoea diagnosis were musculoskeletal disease, hypertension and cardiovascular disease. In multimorbid sleep apnoea patients, hypertension and metabolic diseases including obesity and diabetes, cardiovascular diseases, musculoskeletal diseases and dorsopathies, in different combinations, encompassed the most frequent disease pairs preceding a sleep apnoea diagnosis. Our study adds to the few population-based studies by introducing overall and detailed figures on the burden of comorbidities in sleep apnoea in a nationwide sample and provides up-to-date information on the occurrence of sleep apnoea as well as novel insights into multimorbidity in individuals with incident sleep apnoea

The middle-aged smoker in health care:primary health care use, cardiovascular risk factors, and physician’s help in quitting

Abstract The research focus for smoking and public health has typically been on serious smoking diseases such as cancer and coronary thrombosis, which typically require treatment in a hospital setting at an older age. In this thesis, primary health care utilisation and cardiovascular risk factors according to smoking status were studied in a younger cohort: at age 46 in the Northern Finland Birth Cohort of 1966. Primary health care costs of smokers vs. never-smokers were 28% higher for men and 21% higher for women. Signs of elevated risk of metabolic syndrome and cardiovascular disease were visible: smokers had 20% higher triglycerides, slightly larger waist-to-hip ratio, and type 2 diabetes prevalence was twice as high among smokers than never-smokers after adjustment for covariates. The calculated ten-year risk of a cardiovascular event was twice as high for smokers vs. either never-smokers, former smokers or recent quitters. These results should be seen as early warning signals in primary health care, and cost-effective actions should be taken to prevent later multimorbidity – smoking cessation aid by a physician is very cost effective. Only a minority of smokers receive cessation support from a physician, even though the majority of them wish to quit. In order to understand this discrepancy, a survey was conducted on physicians and smoking cessation. Physicians thought it was their responsibility to try to get the patient to quit, but practical measures to treat smoking dependence were rare. The most commonly reported restrictions for smoking cessation work – lack of time and functional treatment paths – could be addressed by administration and management. The attitudes and experiences of Finnish physicians were in line with the WHO recommendation to improve smoking cessation services and integrate them into health care: 80% were in favour of more resources being directed to smoking cessation services, and less than one third thought that smoking cessation was even somewhat well organised in the Finnish health care system.Tiivistelmä Tupakoinnin terveys- ja talousvaikutusten tarkastelu keskittyy usein myöhemmällä iällä sairaalahoitoa vaativiin tupakkasairauksiin kuten syöpään ja sepelvaltimotautiin. Tässä väitöskirjassa tarkastellaan tupakoinnin ja perusterveydenhuollon käytön sekä sydän- ja verisuonitautien riskitekijöiden yhteyttä nuoremmassa otoksessa: 46 vuoden iässä Pohjois-Suomen vuoden 1966 syntymäkohortissa. Perusterveydenhuollon vuosittaiset kustannukset olivat tupakoivilla korkeammat kuin tupakoimattomilla: miehillä 28% ja naisilla 21%. Merkkejä kohonneesta metabolisen oireyhtymän ja sydän- ja verisuonitautien riskistä oli havaittavissa: tupakoivien triglyseridit olivat 20% korkeammat, heidän lantio-vyötärösuhteensa oli hieman suurempi kuin tupakoimattomilla, ja tyypin 2 diabetes oli heillä kaksi kertaa yleisempää taustamuuttujien vakioinnin jälkeen. Arvioitu riski saada vakava sydän- tai verisuonitapahtuma seuraavan kymmenen vuoden kuluessa oli tupakoivilla kaksi kertaa suurempi kuin heillä, jotka joko eivät olleet ikinä tupakoineet, olivat aiemmin tupakoineet, tai jotka olivat hiljattain lopettaneet. Perusterveydenhuollon tulisi nähdä nämä ilmiöt varhaisina varoitussignaaleina ja ryhtyä kustannusvaikuttaviin toimenpiteisiin myöhemmän multimorbiditeetin ehkäisemiseksi – lääkärin antama tuki tupakoinnin lopettamisessa on erittäin kustannusvaikuttavaa. Vaikka suurin osa tupakoitsijoista haluaa lopettaa, vain vähemmistö saa siihen tukea lääkäriltä. Tämän epäsuhdan ymmärtämiseksi tehtiin kyselytutkimus lääkäreille tupakastavieroituksesta. Lääkärit näkivät velvollisuudekseen yrittää saada tupakoiva potilas lopettamaan, mutta käytännön toimet tupakkariippuvuuden hoitamiseksi olivat harvinaisia. Yleisimmin raportoidut esteet vieroitustyölle – aikapula ja puutteelliset hoitopolut – olivat hallinnon ja johdon ratkaistavissa. WHO:n mukaan Suomella on parantamisen varaa lopettamisen tukipalveluissa ja tupakkariippuvuuden hoidon integroimisessa terveydenhuoltojärjestelmään. Tästä väitöskirjasta käy ilmi, että suomalaisten lääkäreiden asenteet ja kokemukset ovat linjassa WHO:n ohjeistuksen kanssa: 80% kannatti lisäresurssien ohjaamista lopettamispalveluihin ja alle kolmanneksen mielestä tupakastavieroitus toteutui edes jokseenkin hyvin suomalaisessa terveydenhuoltojärjestelmässä

Lower respiratory tract infections among newly diagnosed sleep apnea patients

Abstract Background Sleep apnea is associated with chronic comorbidities and acute complications. Existing data suggest that sleep apnea may predispose to an increased risk and severity of respiratory tract infections. Methods We investigated the incidence of lower respiratory tract infections in the first and second year before and after diagnosis of sleep apnea in a Finnish nationwide, population-based, retrospective case–control study based on linking data from the national health care registers for primary and secondary care from 2015–2019. Controls were matched for age, sex, hospital district, and multimorbidity status. We furthermore analysed the independent effect of comorbidities and other patient characteristics on the risk of lower respiratory tract infections, and their recurrence. Results Sleep apnea patients had a higher incidence of lower respiratory tract infections than their matched controls within one year before (hazard ratio 1.35, 95% confidence interval 1.16–1.57) and one year after (hazard ratio1.39, 95% confidence interval1.22–1.58) diagnosis of sleep apnea. However, we found no difference in the incidence of lower respiratory tract infections within the second year before or after diagnosis of sleep apnea in comparison with matched controls. In sleep apnea, history of lower respiratory tract infection prior to sleep apnea, multimorbidity, COPD, asthma, and age greater than 65 years increased the risk of incident and recurrent lower respiratory tract infections. Conclusions Sleep apnea patients are at increased risk of being diagnosed with a lower respiratory tract infection within but not beyond one year before and after diagnosis of sleep apnea. Among sleep apnea patients, chronic comorbidities had a significant impact on the risk of lower respiratory tract infections and their recurrence